1
|
Cherif LS, Cao-Lei L, Farinelle S, Muller CP, Turner JD, Schroeder H, Grova N. Assessment of 9-OH- and 7,8-diol-benzo[a]pyrene in Blood as Potent Markers of Cognitive Impairment Related to benzo[a]pyrene Exposure: An Animal Model Study. TOXICS 2021; 9:toxics9030050. [PMID: 33800341 PMCID: PMC7998639 DOI: 10.3390/toxics9030050] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/17/2021] [Revised: 02/14/2021] [Accepted: 03/03/2021] [Indexed: 12/27/2022]
Abstract
The potent neurotoxicity of benzo[a]pyrene (B[a]P) has been suggested to be a susceptibility factor accelerating the onset of brain tumours and the emergence of neurobehavioural disturbances. B[a]P has been shown to be neurotoxic, acting directly on both the central and peripheral nervous systems, as well as indirectly via peripheral organs like liver and gut. By using a realistic B[a]P exposure scenario (0.02-200 mg/kg/day, 10 days) in mice, we elucidated brain-specific B[a]P metabolism and at identified hydroxylated B[a]P metabolites in serum which could be used as markers of cognitive impairment. Repeated oral administration of B[a]P led to, at the doses of 20 and 200 mg/kg/day, significant overexpression of Cyp1a1/Cyp1b1 in 2 out of the 3 brain regions considered, thereby suggesting the ability of the brain to metabolize B[a]P itself. At the same doses, mice exhibited a reduction in anxiety in both the elevated plus maze and the hole board apparatus. Concomitantly, B[a]P triggered dose-dependent changes in Nmda subunit expression (Nr1 and Nr2a/Nr2b) in areas involved in cognition. We detected 9-OH-B[a]P and 7,8-diol-B[a]P in serum at the level for which cognitive impairment was observed. We suggest that these metabolites may, in the future be exploited as potent biomarkers of B[a]P-induced cognitive impairments.
Collapse
Affiliation(s)
- Lynda Saber Cherif
- Calbinotox, EA7488, Faculty of Science and Technology, Lorraine University, 54500 Vandoeuvre-lès Nancy, France; (L.S.C.); (L.C.-L.); (H.S.)
| | - Lei Cao-Lei
- Calbinotox, EA7488, Faculty of Science and Technology, Lorraine University, 54500 Vandoeuvre-lès Nancy, France; (L.S.C.); (L.C.-L.); (H.S.)
- Immune Endocrine Epigenetics Research Group, Department of Infection and Immunity, LuxembourgInstitute of Health, L-4354 Esch-sur-Alzette, Luxembourg;
| | - Sophie Farinelle
- Experimental & Molecular Immunology Research Group, Department of Infection and Immunity, Luxembourg Institute of Health, L-4354 Esch-sur-Alzette, Luxembourg;
| | - Claude P. Muller
- Department of Infection and Immunity, Luxembourg Institute of Health, L-4354 Esch-Sur-Alzette, Luxembourg;
- Laboratoire National de Santé, L-3583 Dudelange, Luxembourg
| | - Jonathan D. Turner
- Immune Endocrine Epigenetics Research Group, Department of Infection and Immunity, LuxembourgInstitute of Health, L-4354 Esch-sur-Alzette, Luxembourg;
| | - Henri Schroeder
- Calbinotox, EA7488, Faculty of Science and Technology, Lorraine University, 54500 Vandoeuvre-lès Nancy, France; (L.S.C.); (L.C.-L.); (H.S.)
| | - Nathalie Grova
- Calbinotox, EA7488, Faculty of Science and Technology, Lorraine University, 54500 Vandoeuvre-lès Nancy, France; (L.S.C.); (L.C.-L.); (H.S.)
- Immune Endocrine Epigenetics Research Group, Department of Infection and Immunity, LuxembourgInstitute of Health, L-4354 Esch-sur-Alzette, Luxembourg;
- Correspondence: or ; Tel.: +352-26-970-422
| |
Collapse
|